Sökning: "tumour control"
Visar resultat 31 - 35 av 195 avhandlingar innehållade orden tumour control.
31. Hsp70 in immunotherapy : a potential vector in cancer and viral vaccines
Sammanfattning : New efficient vaccines against cancers and infectious diseases are in demand. In 1993 heat shock protein 70 (hsp70) purified from tumour was shown to elicit tumour protection in mice. It was also shown that the protection was not mediated by the hsp70 itself, but by tumour-specific peptides bound to the molecule. LÄS MER
32. Stereotactic body radiotherapy in non-small cell lung cancer
Sammanfattning : Patients with stage I non small cell lung cancer (NSCLC) are potentially curable. Eradication of the primary tumour is a prerequisite for cure with surgery as standard treatment. LÄS MER
33. Incidence and prognosis of differentiated thyroid cancer in Sweden
Sammanfattning : Non-medullary differentiated thyroid cancer (DTC) is a rare disorder but, nevertheless, among the most common cancers in individuals below 40 years of age. DTC consists of papillary (PTC) and follicular (FTC) thyroid cancer. The prognosis is excellent with an overall 10-year survival of 90 %. LÄS MER
34. Local recurrence after breast conserving surgery in breast cancer
Sammanfattning : The general aim of this thesis was to gain increased insight into the problem of local recurrences after breast conserving surgery for breast cancer. In a population-based cohort of 4,694 women with invasive breast cancer, operated in 1981 to 1990 and followed through 1997, we studied how breast conserving surgery had been adopted into clinical practice. LÄS MER
35. Interferon-alpha based treatment of metastatic malignant melanoma : Effect of immune parameters of importance for monitoring immunotherapy
Sammanfattning : Cutaneous malignant melanoma is a rapidly increasing disease. Most patients are cured by surgical excision of their primary tumour, but for patients with metastatic disease the prognosis is still very poor despite various attempts with chemotherapeutic agents, and during the last decade with immunotherapy, using several different biological agents alone or in combination. LÄS MER